Challenging clinically relevant diagnostic questions related to, e.g., accurate primary staging and restaging after biochemical recurrence, guided biopsy, and treatment monitoring, might be solved for many PCa patients in the case of the regulatory approval of PSMA-targeting imaging agents. The gene discussed is FOLH1; the disease is posterior cortical atrophy.